UK drug regulatory approves COVID antiviral drug Molnupiravir
The risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as soon as possible following a positive COVID-19 test and within five days of symptoms onset.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cardiology | COVID-19 | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Disease | Obesity | Pharmaceuticals